Name: UMIN ID:
Unique ID issued by UMIN | UMIN000015467 |
---|---|
Receipt number | R000017967 |
Scientific Title | Phase II study of erlotinib plus bevacizumab and inserted cisplatin, pemetrexed plus bevacizumab as a 1st-line treatment for advanced non-squamous, non-small cell lung cancer harboring activating EGFR mutations |
Date of disclosure of the study information | 2014/10/18 |
Last modified on | 2018/10/21 20:57:18 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2014/10/18 13:43:53 | ||
2 | Update | 2015/11/16 14:13:23 | Email1 |
|
3 | Update | 2016/07/31 15:09:42 | Name of primary person or sponsor Institute Department Organization Organization Division |
|
4 | Update | 2017/10/20 12:19:38 | Recruitment status Date analysis concluded |
|
5 | Update | 2018/10/21 20:57:18 | Recruitment status |